Asian Markets Slide as New U.S. Strikes on Iran Spark Investor Caution 
Huawei Chip Breakthrough Sparks Rally in Chinese Semiconductor Stocks 
Dollar Slips as Iran Peace Hopes Ease Rate Hike Fears 
SpaceX IPO Hype Raises Questions as Many Major Stock Debuts Underperform Market 
South Korea Central Bank Holds Interest Rates Steady Amid Inflation Concerns 
Samsung Union Dispute Escalates Over Semiconductor Bonus Vote 
Snowflake Stock Soars 30% After Q1 Earnings Beat and Major AWS AI Partnership 
Mega IPOs Like SpaceX and OpenAI Could Reshape S&P 500 and Nasdaq 100 Portfolios in 2026 
Canada and Germany Advance Major LNG Supply Partnership 
U.S.-Iran Talks May Take Days as Oil Prices React to Strait of Hormuz Tensions 
Australia Sues 3M for Over A$2 Billion Over PFAS Firefighting Foam Contamination 
Morgan Stanley Names Top AI Security and Data Center Stocks for 2026 
European EV Sales Surge in April 2026 as Tesla and Chinese Automakers Gain Ground 
Salesforce Q1 FY2027 Earnings Beat Expectations Despite Soft Q2 Revenue Outlook 
RBNZ Holds Interest Rates Steady but Signals More Hikes Ahead in 2026 
Dow Hits Record High as Healthcare and Consumer Stocks Lead Wall Street Rally 
Oil Prices Slip as U.S.-Iran Talks Continue Amid Ceasefire Tensions 
Reckitt Benckiser announced last weekend that it is selling its Mead Johnson Nutrition company in China to Primavera Capital Group. The deal was said to be valued at $2.2 billion.
As per Reuters, while Primavera Capital has already bought Reckitt Benckiser’s infant formula and child nutrition business in China, the latter will still retain an eight percent stake in the China unit of Mead Johnson Nutrition.
Reckitt to incur a loss on the sale
Reckitt Benckiser is expecting to receive around $1.3 billion from the sale, but it is also anticipating a net loss of $3.5 billion on the disposal. The loss is said to be due to intangible assets and re-measurement of goodwill.
In any case, it was in March when it was first reported that Reckitt Benckiser was considering the sale of the Chinese unit of Mead Johnson. The company observed a sluggish sale and launched a strategic review of its infant formula and child nutrition business in China.
In the end, the sale was decided as sales are not going up anywhere, and Reckitt cited the intense competition with local baby formula brands as one of the reasons for the slow income. Also, the low birth rates in China was also blamed for the dwindling sales as there are fewer babies to feed with the infant formula.
The deal between Reckitt and Primavera
As the sale was revealed, Reckitt Beckinser shared that the deal with Primavera Capital includes the sale of the company’s production factories in Guangzhou, China, and at Nijmegen in the Netherlands. Moreover, a royalty-free perpetual and exclusive license of Mead Johnson and Enfa brands in China, including Enfagrow, Enfamil, and Enfinitas, are also included in the agreement.
Then again, it should be noted that this is only in Greater China, as Reckitt still owns and will continue to sell Mead Johnson and Enfa products in other parts of the world.
"We are pleased to acquire the Greater China business of Mead Johnson, a long-established and renowned multinational infant and children nutrition brand,” Primavera Capital Group founder and chairman, Dr. Fred Hu, said in a press release. “As the controlling shareholder, Primavera is committed to serve tens of millions of Chinese mothers and babies and safeguard their well-being.”
Finally, the Reckitt Beckinser and Primavera Capital deal is expected to close within the second half of this year.
